Aplastic Anemia
Conditions
Brief summary
Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia
Interventions
DRUGIticitinib
Sponsors
Incyte Corporation
Eligibility
Inclusion criteria
\-
Exclusion criteria
\-
Outcome results
None listed